Thailand is not an export market: it's a value driver you build before you sell
Most New Zealand and Australian founders in health, skincare and natural ingredients treat Southeast Asia as somewhere to ship product when an order happens to land. Thailand, in that mindset, is an export destination: a distributor takes a container, some product sells, a line of revenue appears, and everyone moves on.
Buyers see it completely differently. To an acquirer, a credible, documented Thailand or Southeast Asian route-to-market is not another revenue line — it is one of the few things that can lift the multiple on the whole business rather than simply adding to the top of it. The founders who understand that difference build the asset before they sell. The ones who don't leave the premium on the table.
Revenue adds to the number; durable access lifts the multiple. A lucky year of orders into Asia flatters your revenue and does little else — a buyer treats it as exactly what it is, a spike that may not repeat. A built position is different in kind: product registered in the right entity, a distributor or clinic footprint that actually exists, and local margin that survives the founder stepping back. That is an asset a buyer can underwrite, and buyers pay for assets, not anecdotes.
A lucky year in Asia adds to your revenue. A built position in Asia adds to your multiple.
What a buyer will actually pay a premium for. Registrations held cleanly by the company, not informally by a distributor who can walk away with them. A route to market with more than one customer in it, so the channel isn't one relationship away from disappearing. Margin that is defensible and documented rather than dependent on a handshake. And a demonstrable understanding of the regulatory reality on the ground — what can be sold, how it must be labelled, and what may be claimed — so the buyer isn't inheriting a compliance problem dressed up as a growth story.
What a buyer discounts, hard. Concentration in a single distributor. Grey-market or parallel-import volume that no one controls and no one can guarantee. Products selling without the registrations they should have. And marketing claims — particularly on anything health, skincare or ingredient-related — that would not survive scrutiny from the Thai FDA or its regional equivalents. Each of these turns Asian revenue from an asset into a liability in diligence, and a diligence liability is priced far more punitively than the revenue was ever worth.
Treat market entry as deal-readiness work. The uncomfortable implication is that if Southeast Asia is going to be part of your equity story, the work has to start eighteen to twenty-four months before you run a process — not in the data room. That is roughly the runway it takes to secure registrations, prove a channel through more than one cycle, and turn a promising market into a documented, durable position a buyer can rely on. Done early, it compounds into value. Done late, it reads as unfinished, and unfinished discounts.
Why this is a Cairns & Company view. We work across New Zealand, Australia, Thailand and the United States, and we have seen both versions of this story play out. We have watched founders capture a genuine premium because their Asian access was real, verifiable and clean — and we have watched others lose it in diligence because what looked like an Asia strategy was really a run of good luck with one distributor. The difference is almost never the science or the product. It is whether the market position was built as an asset or left as an anecdote.
If you are planning a sale in the next two to three years and want your Southeast Asian footprint to lift the price rather than raise questions, that is a conversation worth starting now — while there is still time to build the position properly.